Enovis (NYSE:ENOV) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Enovis has received a "Sell (D-)" rating from Weiss Ratings, highlighting concerns about the company's stock performance.
• Despite the negative rating from Weiss, other research firms like Canaccord Genuity and UBS Group have set buy ratings for the stock, with price targets ranging from $41.00 to $58.00.
• Enovis reported better-than-expected earnings for the last quarter, with an EPS of $0.79, and revenue growth of 7.5% year-over-year.

Enovis (NYSE:ENOV - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other research firms have also recently weighed in on ENOV. Canaccord Genuity Group cut their price target on Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a report on Friday, August 8th. Needham & Company LLC lowered their price target on Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Wells Fargo & Company lowered their price target on Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Evercore ISI lowered their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, UBS Group lowered their price target on Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $51.00.

Enovis Stock Performance

Shares of ENOV stock opened at $31.75 on Wednesday. The stock has a fifty day moving average price of $30.32 and a 200 day moving average price of $31.96. The stock has a market cap of $1.81 billion, a PE ratio of -2.23 and a beta of 1.69. Enovis has a 1 year low of $25.47 and a 1 year high of $49.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.05. The firm had revenue of $564.50 million during the quarter, compared to analysts' expectations of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.Enovis's revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Sell-side analysts forecast that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average price of $29.71 per share, for a total transaction of $74,275.00. Following the transaction, the chief financial officer directly owned 116,729 shares in the company, valued at approximately $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Bradley J. Tandy acquired 3,200 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average price of $31.41 per share, with a total value of $100,512.00. Following the transaction, the senior vice president owned 43,515 shares in the company, valued at $1,366,806.15. This represents a 7.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 12,157 shares of company stock worth $374,760 in the last quarter. Insiders own 2.70% of the company's stock.

Hedge Funds Weigh In On Enovis

A number of large investors have recently modified their holdings of the business. Humankind Investments LLC boosted its position in shares of Enovis by 8.6% during the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company's stock worth $217,000 after acquiring an additional 452 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Enovis by 2.5% during the first quarter. US Bancorp DE now owns 19,031 shares of the company's stock worth $727,000 after purchasing an additional 462 shares during the period. Leisure Capital Management lifted its holdings in shares of Enovis by 2.2% during the first quarter. Leisure Capital Management now owns 22,903 shares of the company's stock worth $875,000 after purchasing an additional 489 shares during the period. Teacher Retirement System of Texas raised its stake in Enovis by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company's stock worth $272,000 after buying an additional 495 shares during the last quarter. Finally, Wedge Capital Management L L P NC raised its stake in Enovis by 0.3% during the second quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company's stock worth $5,111,000 after buying an additional 498 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.